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ABSTRACT: Utilization of safe cytotoxic agents with precise
anticancer activity is considered as the prime focus of cancer
therapeutics research. A greater incentive for such agents arises from
the molecules/drugs that are already being used for other indications.
Ormeloxifene (ORM) is a nonsteroidal, nonhormonal selective estrogen
receptor modulator (SERM), which has been in human use for
contraception purposes. Although in the recent past, many reports have
suggested its emerging role as an anticancer agent, no significant
attention was paid toward generating simple and safe nanoformula-
tion(s) for improved therapeutic activity and tumor cell-specific delivery.
Our aim is to develop nanoformulation(s) of ormeloxifene to improve
its targeted delivery in tumor cells. We developed ormeloxifene
nanoformulation(s) by utilizing various biocompatible polymers. The
optimized formulations with pluronic polymers F127 and F68 show improved nanoparticle characteristics. These formulations
show enhanced cellular uptake that allows ormeloxifene’s intracellular availability. We further evaluated its improved anticancer
activity by performing cell proliferation, flow cytometry, and immunoblotting assays. Overall, this study confirms possible novel
nanoformulation(s) of ormeloxifene to be evolved as a new therapeutic modality for cancer treatment.
■ INTRODUCTION
Pancreatic cancer (PanCa) remains the third leading cause of
cancer-related deaths in the United States.1 Often pancreatic
cancer is diagnosed at the locally advanced stage or when it has
metastasized to distant sites due to nonspecific symptoms.2,3
Such circumstances are likely suitable for chemotherapy.
Among many chemotherapies, 5-fluorouracil, gemcitabine,
gemcitabine plus capecitabine (GemCap), Abraxane plus
gemcitabine, and FOLFIRINOX (5-fluorouracil, leucovorin,
irinotecan. and oxaliplatin or gemcitabine) are commonly
administered to the patients with pancreatic cancer.4−8 These
regimens are associated with numerous side effects such as
nausea, vomiting, myelosuppression, hepatotoxicity, neuro-
toxicity, nephrotoxicity, and ototoxicity.9 In most cases, the
heterogenic tendency of cancer progression not only promotes
the aggressive nature of cancer cells but also facilitates
resistance to chemotherapy.10
Repurposing of already existing drugs for a different
indication has become a new attraction for researchers and is
a clinically viable approach. The process of drug repurposing
(drug reusing or repositioning) is a feasible and affordable
mechanism to create newer therapeutic modalities as the safety
and toxicity profiles of the drug(s) are already well-known.11
Ormeloxifene (ORM, C30H35NO3, a selective estrogen
receptor modulatory molecule) was originally marketed as
oral contraceptive pills in various Asian and African countries
for humans.12,13 Recent literature demonstrates its anticancer
activity against various cancers, such as cervical, ovarian, breast,
head and neck, pancreatic, prostate, and chronic myeloid
leukemia.14−20 A strong rationale to implement this molecule
as an anticancer agent is based on a clinical study of ORM in
70 female patients, which suggests ∼a 38.7% overall response
rate with 6 months treatment.16 Additionally, ormeloxifene
administration showed superior tumor growth inhibition in
both rat and mouse models.19,21−23 These compelling evidence
and excellent safety profile of ormeloxifene promote its clinical
implications as an anticancer agent.24
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Producing various types of anticancer nanoparticle for-
mulations25 can be a step closer toward achieving improved
therapeutic benefits. Nanocarriers are utilized heavily for
delivery of drugs also because they do not alter the loaded
drug’s activities.26 A number of nanoparticle formulations that
have been in clinic or under evaluation in clinical trials guide us
toward achieving this newer path to treat cancer.27,28
Nanoparticles follow either passive or active targeting
mechanisms to reach and accumulate in tumors, and thus,
these can achieve improved therapeutic benefits.29 Therefore,
we hypothesized that encapsulation of ormeloxifene in polymer
matrices would increase its anticancer activity through
increased cellular accumulation, escape from endosomal and
lysosomal degradations, sustained release in the cytoplasm, and
reduced exocytosis. Hence, in the present study, we report a
simple paradigm for the generation of self-assembled polymer/
pluronic-ormeloxifene nanoformulations (ORMNFs) by em-
ploying the solvent evaporation technique with two pluronic
polymers to improve its therapeutic potential in pancreatic
cancer cells. Owing to the miscible nature of this drug and
polymer chain structure of the polymer and pluronic,
ormeloxifene can be entrapped into polymer cores and
delivered in a sustained manner for both in vitro and in vivo
applications. These formulations were optimized for therapeu-
tic applications based on particle size and morphology of
particles and further characterized by transmission electron
microscopy (TEM), dynamic light scattering (DLS), Fourier
transform infrared (FT-IR), and circular dichroism (CD). It
was apparent that formation of nanoparticles is visible within a
few minutes to 60 min depending on the pluronic polymer
employed. Ormeloxifene molecules selectively resided inside
the core of polymer/pluronic micelles. We designed these
formulations based on pluronic’s biocompatible nature. Our
results suggest enhanced anticancer potential of pluronic-
ormeloxifene nano-formulations in MiaPaCa and HPAF-II
pancreatic cancer cell lines as demonstrated by decreased
cellular proliferation and mito-chondrial membrane potential.
This study will facilitate the preclinical development of
ORMNFs as a novel modality for pancreatic cancer manage-
ment.
■ RESULTS
Generation of ORMNFs and ORM’s Compatibility
with Polymers. Pluronic ORM nanoformulations were
prepared using the solvent evaporation method.30 We screened
eight different pluronic polymers for ORMNF preparation and
performed a TEM experiment for screening. Results from
TEM images showed that only two pluronic polymers had
shown uniform particle formation, and both F127-ORM and
F68-ORM nanoformulations were spherical in shape with ∼50
nm particle size (Figure 1). All formulations were compared to
free ORM.
From this experiment, we selected F127-ORM and F68-
ORM for further characterizations. To generate a successful
and stable nanoformulation, it is necessary to validate the
compatibility between the drug and polymer molecules. An
optical microscopic experiment was performed to test ORM’s
compatibility with F127 and F68 polymers. Images from
different timepoints in this experiment confirmed that ORM
was highly dispersed with these two polymers (Figure 2A). It
was evident in this figure that free ORM formed aggregated
clusters as time increased, whereas ORM with F127 and F68
was completely stable or compatible and fully miscible as no
clumps or aggregates of the drug were seen in these images.
Based on this, we propose a possible structure of nanoparticle
formation with pluronic polymer and ORM (Figure 2B).
Physicochemical Characterization of ORMNFs. Particle
size, surface charge, FT-IR, and CD spectra analyses were
performed after each preparation to confirm the ORMNF
production and the presence of ORM in nanoparticles. Results
from DLS analyses revealed that ORMNF particle size and ζ-
potential in 1× PBS aqueous condition (swollen nanoparticles)
were around ∼120 ± 1.7 nm and ∼−10 ± 0.5 mV, respectively
[(Figure 3A) size F127-ORM: 119 ± 1.6 nm, F68-ORM: 123
± 1.8 nm and (Figure 3B) surface charge F127-ORM: −7 ±
0.3 mV, F68-ORM: −9 ± 0.7 mV]. The presence of ORM in
ORMNFs showed characteristic peaks in the FT-IR spectral
analysis (Figure 3C,D).
This suggests that ORM was well dispersed within F127 and
F68 pluronic polymer matrices due to miscibility/compati-
bility. Such property offers superior encapsulation of ORM
into the core of these two polymers. The analysis of
conformational changes at the secondary structure of
ORMNFs after their contact with bovine serum albumin
(BSA) through CD spectra revealed that there were not any
significant changes in the secondary structure of BSA−
ORMNFs (Figure 4A−C). This set of data signifies less
interaction with serum proteins and, thus, suggests longer half-
life and superior adaptability of ORMNFs.
ORMNFs Inhibit Cellular Viability of Pancreatic
Cancer Cells. Cancer cells proliferate in an uncontrolled
manner,31 thus to qualify as an anticancer agent, a drug
candidate should be able to inhibit cancer cell proliferation/
growth. To examine the antiproliferative properties of
ORMNFs, we exposed MiaPaCa and HPAF-II pancreatic
cancer cell lines to drug treatments at different concentrations
for 48 h for morphological changes and MTS assay. The results
from phase-contrast images showed marked deteriorations in
cellular morphology and viability of both MiaPaCa (Figure
5A) and HPAF-II (Figure 5B) cell lines in a dose-dependent
manner. MTS data was in correlation with these findings as
Figure 1. TEM images show particle size of a single particle in
ORMNFs. Eight pluronic polymers were screened for ORMNF
preparation and visualized through TEM. Only F127 and F68 showed
spherical and uniform construction of nanoparticle (white arrows)
formation with ORM. All other pluronic polymers’ nanoparticles were
aggregated/precipitated as clumps, which can be seen in TEM images.
Images were taken at 600 000×. All prepared formulations were
compared with free ORM.
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both cell lines (Figure 5C for MiaPaCa and Figure 5D for
HPAF-II) exhibited significantly decreased cellular prolifer-
ation when compared to free ORM and vehicle controls.
ORMNFs Reduce Colony-Forming Ability of PanCa
Cells. One of the major issues associated with cancer is that
even a single cell is capable of growing into large colonies.32
Thus, this is extremely of high importance to examine
ORMNFs’ potential to reduce the colony-forming ability of
pancreatic cancer cells. Results from this experiment indicated
that ORMNFs significantly inhibited the clonogenicity of
MiaPaCa pancreatic cancer cell lines when compared to free
ORM and vehicle controls (Figure 6A,B). However, F127-
ORM seemed to have a greater inhibitory effect than F68-
ORM in a dose-dependent manner.
ORMNFs Decrease Mitochondrial Membrane Poten-
tial. Depolarization of the mitochondrial membrane is an
Figure 2. (A) Optical microscopic images showing the compatibility of ORM with F127 and F68 polymers in ORMNFs. Dried drops of free ORM
and ORMNF aqueous solution were microscopically examined. Free ORM shows excessive clumps of aggregation as time increases, whereas
ORMNFs show uniform particle formation with no drug aggregation. Images were taken at 200×. (B) Schematic diagram showing the preparation
steps of ORMNFs (F127-ORM and F68-ORM) by a solvent evaporation method.
Figure 3. Physicochemical characterization of ORMNFs. DLS measurements show (A) particle size and (B) surface charge (ζ-potential) of F127-
ORM and F68-ORM nanoformulations. FT-IR spectra of (C) F127-ORM and (D) F68-ORM showing successful encapsulation of ORM in F127
and F68 polymer cores.
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important and one of the early events in the initiation of
apoptosis.33 Therefore, to investigate the ability of ORMNFs
to initiate apoptosis, we performed a flow cytometry
experiment. The tetramethylrhodamine (TMRE) staining
Figure 4. Circular dichroism spectra of ORMNFs. (A−C) Spectra showing secondary structure changes of ORMNFs after BSA interaction. ORM
and its nanoformulations show stability and compatibility with bovine serum albumin protein as no major conformational shifts/changes were
observed in CD spectra.
Figure 5. ORMNFs altered morphology of pancreatic cancer cell lines. (A) MiaPaCa and (B) HPAF-II cell lines were treated with ORMNFs and
free ORM for 48 h and were imaged with a phase-contrast microscope at 200× after a careful visualization. Images clearly showed a decreased
number of cells and apoptosis-like signs such as membrane blebbing and shrinkage. ORMNFs inhibited cell proliferation of pancreatic cancer cell
lines. (C) MiaPaCa and (D) HPAF-II cell lines were treated with free ORM and ORMNFs at different concentrations for 48 h. Utilizing the MTS
method, optical density was recorded at 490 nm to measure cellular proliferation. Results were normalized to free ORM and vehicle controls
ETOH, F127, and F68. Error bars show standard error of the mean (SEM), n = 3. *p < 0.05.
Figure 6. ORMNFs reduced colony-forming ability of pancreatic cancer cells. (A) Images showing reduced clonogenicity of MiaPaCa cell lines.
Cells were treated for 14 days with lower concentrations of ORM and ORMNF treatment. At the termination, cells were washed, fixed, stained, and
imaged. (B) Graph bars show quantitation of these images. Colonies (∼50 cells) were manually counted. Results were compared to free ORM and
vehicle controls ETOH, F127, and F68. Error bars show SEM, n = 3. *p < 0.05.
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method was used to detect the depolarization of the
mitochondrial membrane. Our data from flow cytometry
revealed that ORMNFs significantly reduced the mitochondrial
membrane potential at the highest concentration of 30 μM
when compared to free ORM in both MiaPaCa (Figure 7A)
and HPAF-II (Figure 7B) cell lines.
ORMNFs Regulate Expression of Key Apoptotic
Molecules. It was imperative to further confirm the apoptotic
events at the molecular levels. To do this, we examined the
expression level of two key players in apoptosis, namely,
poly[ADP-ribose] polymerase (PARP) and B-cell lymphoma-
extra-large (Bcl-xl)34 by utilizing immunoblotting. During
apoptosis, total PARP undergoes degradation, and, thus, it
increases the amount of cleaved PARP. Bcl-xl is an
antiapoptotic marker, which promotes cell growth/surviv-
al.35,36 Figure 8A clearly illustrates that when MiaPaCa cells
were treated with ORMNFs mainly with a higher concen-
tration of 30 μM, apoptosis was induced as increased
expression of cleaved PARP and decreased expression of Bcl-
xl were observed when compared to free ORM and the control
group.
ORMNFs Induce Ultrastructural Morphological Alter-
ations. TEM imaging technique was utilized to evident the
morphological changes and signs of apoptosis ultrastructurally
in MiaPaCa cell lines. After 48 h of ORMNF (F127-ORM and
F68-ORM) and free ORM exposure at 30 μM concentration,
clear signs of apoptosis were evident. TEM micrographs
revealed that after 6 h of drug treatment, cells did not show any
obvious morphological changes as the nucleus and cell
membrane were intact, whereas at later hours (48 h), cells
were presented with ultrastructural changes as distorted
nucleus and apoptotic vacuoles (endosomal and lysosomal)
were observed (Figure 8B). These vacuoles are formed when
the mitochondrial membrane depolarizes, and cells undergo
apoptosis.33 Depolarization in the membrane of the mitochon-
dria disintegrates the membrane wall, and, thus, it enhances the
permeability and swelling of the organelle.33 ORMNF-treated
cells showed more prominent apoptotic structures than free
ORM and control cells. This set of data clearly indicated that
ORMNFs were successfully delivered to pancreatic cancer
cells, which further increased the therapeutic potential of
ORMNFs in these cells.
■ DISCUSSION
Pancreatic cancer is a devastating disease with a poor 5 year
survival rate of only ∼8%.1 The treatment for pancreatic cancer
requires cytoreductive surgery with possible chemotherapy.37
Although chemotherapy is initially responsive, these tumors,
Figure 7. ORMNFs decreased mitochondrial membrane potential. (A) MiaPaCa and (B) HPAF-II cell lines were exposed to free ORM and
ORMNFs at 10, 20, and 30 μM concentrations for 24 h, stained with TMRE, and analyzed by a flow cytometer to measure depolarization in the
mitochondrial membrane of cells. Results were normalized to free ORM and control cells with no treatment. Error bars show SEM, n = 3. *p <
0.05.
Figure 8. ORMNF-induced apoptosis in MiaPaCa pancreatic cancer cell lines. (A) Immunoblots for apoptosis-related protein expression. MiaPaCa
cells were treated with free ORM and ORMNFs for 24 h and processed for immunoblotting to detect the expression levels of PARP and Bcl-xl
proteins. β-actin was used as a loading control. Treatment groups were compared to control cells with no treatment. (B) TEM images for
ultrastructural morphological changes. MiaPaCa cells were treated with 30 μM free ORM and ORMNFs for 6 and 48 h and processed for TEM
imaging to visualize the morphological changes ultrastructurally and to confirm apoptotic cell death. The control group represents cells with no
drug treatment. Treated cells were compared to control cells. Images were taken at 3000×.
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unfortunately, relapse due to the drug resistance.10 Thus,
identifying new therapeutic molecules are urgently required to
treat this deadly cancer. Enormous literature supports that
nanocarrier(s) showed promising potential for the delivery of
anticancer drugs.28,38,39 Additionally, nanoparticle-based anti-
cancer drug formulations provide significant advantages over
conventional small-molecule drug(s) by minimizing non-
specific toxicity and enhancing therapeutic efficacy at tumors,
and this is feasible due to their large surface-to-volume
ratio.40−42
Ormeloxifene is a proven clinical oral contraceptive agent for
humans and approved in India.24 In the recent past,
considerable work has been focused to examine the
mechanistic role of ormeloxifene in cancer, but not many
strategies exist for efficient delivery of ormeloxifene to cancer
cells. Earlier studies by Gupta and Jabrail43,44 have shown that
physically cross-linked microspheres of chitosan with different
molecular weights and degree of deacetylation offer sustained
release of ormeloxifene. Our recent investigations are the first
examples of nanoparticle formulation of ormeloxifene (poly-
[lactic-co-glycolic acid]-based nanoparticles), which demon-
strated excellent tumor growth reduction.22,23 Previous efforts
from our group have demonstrated that improved therapeutic
effects of curcumin (an anticancer drug) were achieved using
β-cyclodextrin and poly(β-cyclodextrin) inclusion complex,
polymer nanoparticles, nanogels, and magnetic nanoparticle
drug delivery vehicles.45−48 Polymeric micelles have also
shown significance as a drug carrier for superior therapeutic
potential.49−51 In the process of preparing these polymeric
micelles, spontaneous formation of drug nanoparticle aggrega-
tion occurs by simply mixing the drug molecules and polymer
micelles together, this results in a core−shell structure of the
drug nanoparticle aggregates, and it is the main advantage over
other nanocarriers.52,53 A cremophor EL free, paclitaxel-
encapsulated poly(ethylene glycol)-b-poly-(D,L-lactic acid)
(PEG-PLA) polymer micelle formulation under a trade name
Genexol-PM has been approved by the Food and Drug
Administration (FDA) for treating breast cancer.54,55 Another
polymeric micelle based on Pluronic L61/F127-mixed micelles
(SP1049C from Supratech Pharma Inc.) has successfully
completed Phase II clinical trial for doxorubicin delivery to
esophageal and gastroesophageal cancers.56 Selection of the
type of block copolymers or pluronic polymers is a critical task,
and it depends on the type of the drug that needs to be
formulated. Pluronic polymers, mostly composed of poly-
(ethylene oxide) (PEO) and poly(propylene oxide) (PPO),
have widely been studied to load various anticancer agents.53,57
These polymers have also been demonstrated to act as
inhibitors of P-gp, which can sensitize tumor cells for
therapeutic agents.58 In this context, developing a systemic
formulation of ormeloxifene would be highly valuable to
overcome conventional systemic barriers and to facilitate
intracellular drug accumulation at the tumor site.
In this current investigation, ormeloxifene-encapsulated
polymer micelle nanoformulations (ORMNFs) were success-
fully designed, developed, and tested for superior anticancer
activity in MiaPaCa and HPAF-II pancreatic cancer cell lines.
We employed various analytical tools to characterize ORMNFs
and examined their anticancer activity using the MTS
technique for cell proliferation, flow cytometry for mitochon-
drial membrane depolarization, and immunoblotting for
protein expression. DLS data of ORM-encapsulated nano-
formulations exhibited a particle size of ∼120 nm and surface
charge of ∼−10 mV. Transmission electron microscopy images
of ORMNFs indicated a smooth surface morphology for F68-
ORM, whereas F127-ORM demonstrated an aggregative
pattern of drug molecules and particle size of ∼50 nm for
both nanoformulations. CD spectra and optical images showed
that ORMNFs are highly compatible and stable with serum
albumin and within the formulation itself. The cytotoxic effects
of free ORM and ORM nanoformulations exhibited a dose-
dependent effect in decreased cell proliferation for both
pancreatic cancer cell lines and in reduced colony-formation
ability for MiaPaCa pancreatic cancer cell lines. At all
treatment concentrations, ORM nanoformulations showed
higher toxicity than free ORM. This enhanced cytotoxicity can
be attributed to greater uptake of nanoformulations by the
cells, which is a widely explained phenomenon. Additionally,
ORMNFs induced apoptosis in these pancreatic cancer cell
lines as evident by a decreased mitochondrial membrane
potential, and the altered expression levels of PARP and Bcl-xl,
two important apoptotic markers. Moreover, ORMNFs caused
obvious ultrastructural changes in these cells as vacuole
formations were observed with TEM, which further confirmed
the induction of apoptosis.
Remarkably, an enhanced anticancer potential of ORMNFs
indicates the feasibility for developing these novel nanoparticle
drug formulations as a lead therapeutic modality for pancreatic
cancer, provided that, additional studies are warranted for its
preclinical and clinical investigations. Additionally, since
ormeloxifene has already been in human use for oral delivery,
this novel formulation can be delivered orally as well as
intravenously.
■ MATERIAL AND METHODS
Chemicals and Cell Culture. All chemicals and reagents
used in this work were purchased from Sigma-Aldrich
Corporation (St. Louis, MO) unless otherwise mentioned.
MiaPaCa and HPAF-II pancreatic cancer cell lines were
purchased from ATCC (American Type Culture Collection)
(Manassas, VA). These pancreatic cancer cell lines were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
and DMEM-F12 (Gibco, Gibco Laboratories, Gaithersburg,
MD), respectively, with supplements: 4500 mg/L glucose, 4.00
mM L-glutamine, 10% heat-inactivated FBS (Atlantic Bio-
logicals, Lawrenceville, GA), and 5 mL of 1× antibiotic/
antimycotic (Sigma, St. Louis, MO). Cell lines were cultured at
37 °C under a humidified atmosphere of 5% CO2. All of the
cell lines used in this study were authenticated and checked for
mycoplasma and other infections.
Generation of ORM Nanoformulations (ORMNFs).
Eight different pluronic polymers, poly(ethylene glycol)-
block-poly(propylene glycol)-block-poly(ethylene glycol), MW
1100 (L31), 1900 (L35), 2000 (L61), 2900 (L64), 4400
(L121), 5800 (P123), 8400 (F68), and 12 400 (F127), were
screened to prepare ORM nanoformulations following a
solvent evaporation technique30 with some modifications.
Briefly, 10 mg of ORM in 1 mL of ethanol (ETOH) and 20 mg
of the polymer in 1 mL of water were dissolved separately.
Next, 100 μL of ORM solution was added dropwise to 900 μL
of the polymeric solution, and it is then mixed with 1 mL of
water under magnetic stirring at 800 rpm for about a minute in
a 2 mL glass vial. Ethanol was evaporated under stirring
overnight at room temperature to obtain a homogenous ORM
nanoparticle formulation. This homogeneous suspension was
filtered through a 0.45 μm syringe filter (Millex-LG, Millipore
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Co.) and lyophilized for further long-term use. This technique
allows ormeloxifene to disperse in polymer matrices or self-
assembled into pluronic micelles.
Compatibility of ORMNFs. Before testing these newly
formed formulations in vitro and in vivo, it was imperative to
evaluate the stability/compatibility between drug and polymer
molecules. To determine the stability/compatibility of
ORMNFs, we prepared 500 μg/mL aqueous solutions of
ORMNFs, free ORM, and performed a visual evaluation of
nanoparticle formation using the optical microscopy analysis.
For this experiment, 2−3 drops of these freshly prepared
solutions were placed onto a glass slide and were air-dried in a
fume hood overnight. Slides were protected from exposing to
dust and light, and the next morning, slides were imaged using
optical microscopy (Olympus BX 41 microscope; Olympus,
Center Valley, PA) at 200×.
Physicochemical Characterization. ORMNFs were
characterized by various techniques including transmission
electron microscopy (TEM), dynamic light scattering (DLS),
Fourier transform infrared spectroscopy (FT-IR), and circular
dichroism (CD).
Transmission Electron Microscopy. The particle size and
morphology of ORMNFs were examined using a JEOL-1210
transmission electron microscope (JEOL Ltd., Tokyo, Japan).
For this study, a drop of ORMNFs (1 mg/mL suspension in
water) was dispensed on a thin film of amorphous carbon
deposited on a 200 mesh formvar-coated copper TEM grid
(grid size: 97 μm) (Ted Pella, Inc., Redding, CA), followed by
(2% w/v of uranyl acetate) staining solution, and air-dried.
These nanoparticles on the TEM grid were viewed and imaged
under TEM operating at 60 kV.
Dynamic Light Scattering. The particle size distribution
and surface charge (zeta potential, ζ) of prepared ORMNFs
were measured by the laser diffraction method using a Delsa
Nano C particle size analyzer (Beckman Coulter, Brea, CA).
After 2 min equilibration of the instrument, all of the
measurements were performed at 25 °C. For measurements,
ORMNFs (1 mg/mL suspension) were ultrasonicated for 30 s
and transferred into a four-sided, clear plastic cuvette or a
capillary ζ-potential cell for size distribution and ζ-potential.
All results were the mean of 3 test runs.
Fourier Transform Infrared. To confirm ormeloxifene’s
successful assembly in the pluronic polymer matrix, the FT-IR
spectrometry experiments were performed. Using a Perkin-
Elmer Spectrum BX spectrophotometer (Perkin-Elmer Inc.,
Norwalk, CT), FT-IR spectra were obtained for ORM and
ORMNFs. For each FT-IR sample acquisition, 32 scans at the
speed of 2 cm−1 were recorded, and an average of these scans
was presented as the FT-IR spectrum. The spectral range was
chosen from 4000 to 650 cm−1.
Circular Dichroism. A Jasco 815 circular dichroism (CD)
spectrometer (JASCO International Inc., Ltd., Japan) was
utilized to measure the changes in the secondary structure of
the protein (bovine serum albumin, BSA) upon their
interaction with ORMNFs. For this experiment, we used
various concentrations of free ORM and ORMNFs (10−40
μM) with 10 μM of bovine serum albumin (BSA). The CD
spectra of BSA or BSA-ORM or BSA−ORMNFs were
recorded from 200 to 260 nm in a 1 cm quartz cell at 25 °C.
Cell Viability Assay. To perform cell proliferation/viability
assay, 2 pancreatic cancer cell lines MiaPaCa and HPAF-II
were seeded at 5 × 103 cells/well density in 96-well plates and
allowed to adhere overnight. The next day, cells were treated
with 10, 15, 20, 25, 30, and 40 μM concentrations of either free
ORM or ORM nanoformulations (ORMNFs) for 48 h. ETOH
and blank pluronics were used as vehicle controls for ORM
and ORM nanoformulations, respectively. After 48 h, cells
were washed twice with phosphate-buffered saline (PBS) and
microscopically visualized for imaging. Images were captured
with an Olympus microscope (Olympus, Center Valley, PA).
Further, 25 μL of MTS reagent (CellTiter 96 AQueous,
Promega Corporation, Madison, MI) was added to each well,
and plates were incubated for the next 2−3 h. Post-incubation,
absorbance was recorded at 490 nm spectrophotometrically
using a BioMate 3 microplate reader (Thermo Fisher
Scientific, Pittsburgh, PA). Each experiment was done in
replicates of 6 and repeated 3 individual times.
Colony-Formation Assay. We utilized MiaPaCa cell lines
for further long-term treatment evaluation of ORMNFs. At the
density of 500 cells/well in 6-well plates, cells were plated and
allowed to attach. When cells were fully attached usually in
24−30 h, different concentrations of ORMNFs were given to
the cells and allowed to further incubate for 14−15 days. On
the day of termination, plates were washed with PBS, fixed
with ice-cold methanol (MEOH), stained with hematoxylin,
and again washed with running water. Plates were then air-
dried and imaged with a gel doc (BioRad, Hercules, CA).
Colonies were manually counted, and each experiment was
performed three individual times.
Mitochondrial Membrane Potential (ΔΨM) using
TMRE. 2 × 105 MiaPaCa and HPAF-II cells were plated per
well in 6-well plates and allowed to adhere overnight. The next
day, cells were treated with ORM and ORMNFs at 10, 20, and
30 μM concentrations for 24 h. After 24 h, cells were washed
with PBS, trypsinized, and centrifuged at 1000 rpm for 5 min
to obtain the final pellet. The pellet was then resuspended in 1
mL PBS with 50 nM tetramethylrhodamine(TMRE, ethyl
ester) stain containing in it, and cells were further incubated
for 25−30 min in the dark at 37 °C. After the indicated time,
cells were analyzed under the FL2 channel using a BD Accuri
C6 flow cytometer. The experiment was performed three
independent times.
Immunoblotting. For immunoblotting, 5 × 106 MiaPaCa
cells were plated in a 100 mm dish and allowed to adhere
overnight. The next morning, cells were treated with ORM and
ORMNFs at 20 and 30 μM concentrations for the next 48 h.
Next, cells were washed with PBS, and lysates were collected
by scraping cells with SDS buffer (Santa Cruz Biotechnology,
Santa Cruz, CA) and sonicated for 30−40 s during freeze−
thaw cycles. The SYPRO Orange (Invitrogen, Carlsbad, CA)
method was employed further to quantify the protein
concentration. 50 μg of protein from each sample was loaded
and separated by 4−20% SDS-PAGE gel electrophoresis at 150
V for 60 min. Proteins were then transferred onto a
poly(vinylidene difluoride) (PVDF) membrane at 100 V for
90 min. The membranes/blots were next blocked with 5%
skimmed milk in tris buffered Saline with Twin 20 (TBST) at
room temperature for 1 h and further incubated with primary
antibodies specific for poly[ADP-ribose] polymerase (PARP),
B-cell lymphoma-extra-large (Bcl-xl), and β-actin at 4 °C for
overnight. The next day, blots were washed thrice with TBST
and incubated with goat antirabbit/mouse secondary antibod-
ies for 1 h at room temperature. For protein signal detection,
blots were washed again thrice with TBST for 15 min per wash
and soaked in with a Lumi Light reagent (Roche, Nutley, NJ)
and imaged with a gel doc (BioRad, Hercules, CA).
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Ultrastructure Morphological Analysis with TEM.
TEM has become a powerful tool to study the morphological
changes at the ultrastructural level and detect apoptosis in
cells.59 To understand the ORMNF-induced apoptosis ultra-
structurally, 1 × 106 MiaPaCa cells per 100 mm dish were
plated and allowed to adhere overnight. The next day, cells
were exposed to 30 μM of ORMNFs or equivalent free ORM
for 6 and 48 h. At the indicated timepoints, cells were washed
with PBS, trypsinized, centrifuged, and fixed with 4%
glutaraldehyde (v/v) in 0.1 M cacodylate buffer and followed
by 1% OsO4 solution fixation. Further, cells were washed with
cacodylate buffer, and a graded series of acetone from 35 to
100% (35, 50, 75, 95, and 100%) was used to dehydrate the
cell pellets. Next, cell pellets were embedded with low viscosity
Spurr resin. Ultrathin sections of 70−90 nm thickness were
cut/sectioned from these resin blocks utilizing an ultra-
microtome. Cut sections were then transferred into 97 μm
sized TEM grids (Ted Pella Inc., Redding, CA) and stained
with uranyl acetate and lead acetate. After staining, these
sections were visualized with transmission electron microscopy
for ultrastructural changes.
Statistical Analysis. All statistical calculations were
performed using Prism 6.0 (GraphPad Software Inc., San
Diego, CA). The data are expressed as mean ± standard error
of the mean (SEM). Unpaired Student’s t-test was used for
comparison of two groups. Differences were considered
statistically significant when the p-value was <0.05.
■ CONCLUSIONS
To conclude, this work provides a proof-of-concept foundation
that pluronic polymers can be a successful delivery vehicle for
ormeloxifene. ORMNFs had a mean particle size of ∼120 nm
and ζ-potential of ∼−10 mV. These values are comparable
with existing FDA-approved nanoformulations for cancer
therapeutics.60 Furthermore, these formulations exhibited
superior anticancer activities against pancreatic cancer cell
lines than free ormeloxifene. ORM nanoformulations induced
apoptosis through decreasing the mitochondrial membrane
potential and altering the expression of apoptosis-related two
key proteins and the ultrastructure of these cells. Based on
these results, we believe that ORM nanoformulations could be
a promising treatment regimen for pancreatic cancer. These
results are warranted to further examine the anticancer efficacy
of ORM nanoformulations in clinically relevant mouse models.
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